Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study 359

Prostate

Volumn 39, Issue 4, 1999, Pages 234-239

  Brawer, Michael K ^a   Lin, Daniel W ^b   Williford, William O ^c   Jones, Karen ^c   Lepor, Herbert ^d  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BPH; Finasteride; PSA; Terazosin

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; TERAZOSIN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 0033152574     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990601)39:4<234::AID-PROS3>3.0.CO;2-4     Document Type: Article

References (40)

1. Silverberg E, Boring CC, Squires TS. Cancer statistics. CA Cancer J Clin 1990;40:9-26.
2. Seidman H, Mushinski MH, Geib SK, Silverberg E. Probabilities of eventually developing or dying of cancer - United States, 1985. CA Cancer J Clin 1985;35:36-56.
3. Oesterling JE. Prostate specific antigen. A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
4. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project: Findings on the detection of early prostate cancer in 2425 men. Cancer 1991;67:2949-2958.
5. Labrie F, DuPont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Edmond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-852.
6. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ulrrasonography, digital rectal examination and prostate-specific antigen. J Urol 1990;143:1146-1152.
7. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol 1989;141:1076-1083.
8. Lee F, Torp-Pedersen S, Littrup PJ, McLeary RD, McHugh TA, Smid AP, Stella PJ, Borlaza GS. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989;170:29-32.
9. Madsen FA, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia. Urol Clin North Am 1995;22:291-298.
10. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-539.
11. Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 1995;332:99-109.
12. McConnell JD. Benign prostatic hyperplasia. Hormonal treatment. Urol Clin North Am 1995;22:387-400.
13. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81:814-819.
14. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
15. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-1191.
16. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-294.
17. Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with Finasteride. Eur Urol 1995;27:267-273.
18. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate-specific antigen: review of available data. J Urol 1996;155:3-9.
19. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993;22:31-37.
20. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol Clin North Am 1993;20:627-636.
21. Caine M, Pfau A, Perlberg S. The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255-263.
22. Brawer MK, Adams A, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 1993;2:929-935.
23. Lepor H, Knapp-Maloney G, Sunshine H. A dose titration study evaluating terazosin, a selective, once-a-day alpha-1-blocker for the treatment of symptomatic benign hyperplasia. J Urol 1990;144:1393-1397.
24. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P. A randomized, placebo-controlled multi-center study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-1474.
25. Milam D, Oesterling JE, Roehrborn CG, Auerbach S, Padley RJ. Serial prostate-specific antigen measurements in patients with clinical benign prostatic hyperplasia enrolled in a randomized, double-blinded, placebo-controlled study with terazosin [abstract]. J Urol 1995;153:396A.
26. Jones EA, Ploch NR, Brawer MK. Serum PSA in men with symptomatic BPH treated with terazosin [abstract]. J Urol 1994;151: 510A.
27. Brown JA, Peterson DD, Lieber MM, Oesterling JE. Terazosin and finasteride both lower the serum prostate-specific antigen (PSA) level in men with benign prostatic hyperplasia (BPH) [abstract]. J Urol 1996;155(Supplement 5):424A.
28. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate-specific antigen: results of the second year. J Urol 1993;150:106-109.
29. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, Walsh PC. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995;45:591-596.
30. Porter JR, Hayward R, Brawer MK. The significance of short-term PSA change in men undergoing ultrasound guided prostate biopsy [abstract]. J Urol 1994;151:293A.
31. Jacobsen SJ, Klee GG, Lilja H, Wright GL Jr, Oesterling JE. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology 1995;45:447-453.
32. Wener MH, Daum PR, Brawer MK. Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995;41:1730-1737.
33. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. Urology 1993;42:390-297.
34. Brawer MK, Daum P, Petteway JC, Wener MH. Assay variability in serum prostate-specific antigen determination. Prostate 1995;27:1-6.
35. Brawer MK, Bankson DD, Haver VM, Petteway JC. Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. Prostate 1997;30:269-273.
36. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol 1996;155:1977-1980.
37. Dejter SW, Jr., Martin JS, McPherson RA, Lynch JH. Daily variability in human serum PSA and prostatic acid phosphatase: a comparative evaluation. Urology 1988;32:288-292.
38. Glenski WJ, Klee GG, Bergstralh EJ, Oesterling JE. Prostate-specific antigen establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate 1992;21:99-110.
39. el-Shirbiny AMF, Nilson T, Pawar HN. Serum PSA hourly change/24 hours compared with prostatic acid phosphatase. Urology 1990;35:88-92.
40. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997;157: 2183-2190.